ciprofloxacin + fenofibrate

Ciprofloxacin + fenofibrate is a non-standard drug combination consisting of ciprofloxacin, a second‑generation fluoroquinolone antibiotic, and fenofibrate, a fibrate lipid‑modifying agent. Ciprofloxacin acts by inhibiting bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and transcription and providing broad Gram‑negative and some Gram‑positive coverage for susceptible infections.[3] Fenofibrate is a prodrug that is converted to fenofibric acid, which activates peroxisome proliferator‑activated receptor‑alpha (PPARα) to increase fatty acid oxidation, reduce triglycerides, and modestly increase HDL cholesterol in primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia.[2][4] This pairing is not an established fixed‑dose product and is not used as a recognized therapeutic combination for any specific indication; when co‑administered, the drugs retain their independent mechanisms and indications, and available evidence does not support any specific therapeutic benefit of combining them (for example, there is no evidence that the combination improves outcomes in urinary tract infection beyond ciprofloxacin alone).[3][4][5]